HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
← catalyst calendarSponsored by Intellia Therapeutics (industry) · NTLA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
80actual
Sites
29
Countries
Australia, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-15 | actual | When the study began enrolling |
| Primary completion | 2026-02-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hereditary Angioedema
Interventions
- Biological: NTLA-2002
- Biological: Normal Saline IV Administration
Primary outcome
what the primary-completion date above is the date OFTime-normalized number of Investigator-confirmed HAE attacks
measured From Week 5 through Week 28
Publications
- PMID 42294842 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NTLA's whole pipeline · Catalyst calendar · Every registered study · What changed